Selective maintenance of a recombinant gene in a population of vaccine cells
AssigneeWashington University
InventorRoy Curtiss, III
Life of this patent
Estimating the term…
Loading patent…
AssigneeWashington University
InventorRoy Curtiss, III
Estimating the term…
The invention encompasses methods of maintaining desired recombinant genes in a genetic population of cells expressing the recombinant gene. The methods utilize mutant cells which are characterized by a lack of a functioning native gene encoding an enzyme which is essential for cell survival, wherein this enzyme catalyzes a step in the biosynthesis of an essential cell wall structural component and the presence of a first recombinant gene encoding an enzyme which is a functional replacement for the native enzyme, wherein the first recombinant gene cannot replace the defective chromosomal gene. The first recombinant gene is structurally linked to a second recombinant gene encoding a desired product. Loss of the first recombinant gene causes the cells to lyse when the cells are in an environment where a product due to the expression of the first recombinant gene is absent. The invention also encompasses methods of creating and isolating mutant cells with the above characteristics. The cells of the invention are useful for commercial production of desired products, for components of vaccines for immunizing individuals, and for release into the environment.
A live bacterial carrier for a vaccine for immunizing an individual, said carrier comprising an avirulent derivative of a pathogenic strain of bacteria characterized by:
A composition for stimulating an immune response in an individual comprising a live avirulent derivative of a pathogenic strain of bacteria characterized by:
A method of preparing a bacterial carrier for a vaccine for immunization of an individual, said method comprising:
An immunogenic composition comprising an avirulent derivative of a pathogenic strain of bacteria characterized by:
Dependencies are inferred from the claim text.